**Supplementary material**

**Figure S1 —** Vaccine uptake, from week 1 to 26 of 2021 in Mainland Portugal



**Figure S2** — Number of people vaccinated with mRNA vaccine by brand, from week 1 to 26 of 2021 in Mainland Portugal



**Figure S3** — mRNA vaccine coverage per age group and week, from week 1 to 26 of 2021 in Mainland Portugal



**Figure S4 —** Relative frequency of age groups of reported confirmed cases over 40 years to the national surveillance system and study sample, from week 20 to 26 of 2021 in Mainland Portugal



**Case-case study design description**

The most common approach of vaccine effectiveness (VE) studies is test-negative case-control design, where VE is estimated comparing odds of vaccination between positive (cases) and negative (controls) (VE=(1-OR)\*100%).

Variant-specific vaccine effectiveness estimates in test-negative design (TND) studies are obtained restricting comparisons to cases positive to specific variant versus negative controls (Table S1)

**Table S1** — Classification of cases by vaccination and positivity status

|  |  |  |  |
| --- | --- | --- | --- |
|   | Delta+ | Alpha+ | Negative controls |
| Vaccinated | a | k | b |
| Unvaccinated | c | m | d |

 resulting in vaccine effectiveness estimates

$VE\_{Delta}=\left(1-OR\_{Delta}\right)×100\%$ and, $VE\_{Alpha}=\left(1-OR\_{Alpha}\right)×100\%$,

where $OR\_{Delta}$ and $OR\_{Alpha}$ are obtained as follows:

$OR\_{Delta}=\frac{a×d}{c×b}$ $OR\_{Alpha}=\frac{k×d}{m×b}$

Only positive cases are considered in case-case design, and odds of vaccination are compared directly between two variants. Considering Delta cases as cases of interest and Alpha cases as a reference group, the case-case OR is estimated as:

$$OR\_{case-case}=\frac{a×m}{c×k}$$

that is mathematically equivalent to the ratio of two variant-specific OR obtained from TND:

$\frac{OR\_{Delta}}{OR\_{Alpha}}$=$\frac{a×d}{c×b}÷\frac{k×d}{m×b}$ =$\frac{a×d×m×b}{c×b×k×d}$=$\frac{a×m}{c×k}=OR\_{case-case}$

The case-case approach allows to formally test whether the difference between variant-specific odds ratios is statistically significant and infer variant-specific vaccine effectiveness (Figure S5).

**Figure S5** — Comparison diagram between test-negative design and case-case design

